natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
Company profile
Ticker
NTRA
Exchange
Website
CEO
Stephen Chapman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NTRA stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
5 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Natera Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
8-K
Natera Acquires Reproductive Health Assets from Invitae
22 Jan 24
Transcripts
NTRA
Earnings call transcript
2024 Q1
9 May 24
NTRA
Earnings call transcript
2023 Q4
28 Feb 24
NTRA
Earnings call transcript
2023 Q3
8 Nov 23
NTRA
Earnings call transcript
2023 Q2
3 Aug 23
NTRA
Earnings call transcript
2023 Q2
3 Aug 23
NTRA
Earnings call transcript
2023 Q1
9 May 23
NTRA
Earnings call transcript
2022 Q4
28 Feb 23
NTRA
Earnings call transcript
2022 Q3
8 Nov 22
NTRA
Earnings call transcript
2022 Q2
6 Aug 22
NTRA
Earnings call transcript
2022 Q1
8 May 22
Latest ownership filings
SC 13G/A
JPMORGAN CHASE & CO
7 Jun 24
4
Gail Boxer Marcus
31 May 24
4
Solomon Moshkevich
30 May 24
4
John Fesko
30 May 24
4
Rowan E Chapman
30 May 24
144
Notice of proposed sale of securities
30 May 24
144
Notice of proposed sale of securities
28 May 24
4
Jonathan Sheena
24 May 24
144
Notice of proposed sale of securities
20 May 24
4
Jonathan Sheena
17 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 813.82 mm | 813.82 mm | 813.82 mm | 813.82 mm | 813.82 mm | 813.82 mm |
Cash burn (monthly) | (no burn) | (no burn) | 24.77 mm | 31.85 mm | (no burn) | 11.57 mm |
Cash used (since last report) | n/a | n/a | 57.18 mm | 73.53 mm | n/a | 26.71 mm |
Cash remaining | n/a | n/a | 756.64 mm | 740.29 mm | n/a | 787.11 mm |
Runway (months of cash) | n/a | n/a | 30.5 | 23.2 | n/a | 68.0 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 401 |
Opened positions | 179 |
Closed positions | 36 |
Increased positions | 91 |
Reduced positions | 99 |
13F shares | Current |
---|---|
Total value | 10.01 tn |
Total shares | 125.16 mm |
Total puts | 262.50 k |
Total calls | 249.00 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 11.04 mm | $1.01 tn |
Alger Associates | 8.97 mm | $0.00 |
JPM JPMorgan Chase & Co. | 7.36 mm | $672.96 bn |
Fred Alger Management | 6.55 mm | $598.78 bn |
BLK Blackrock | 6.49 mm | $593.20 bn |
Farallon Capital Management | 3.93 mm | $359.23 bn |
AMP Ameriprise Financial | 3.44 mm | $314.80 bn |
IVZ Invesco | 3.21 mm | $293.60 bn |
STT State Street | 2.72 mm | $249.04 bn |
Millennium Management | 2.64 mm | $241.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 May 24 | Marcus Gail Boxer | Common Stock | Sell | Dispose S | No | No | 110.165 | 2,000 | 220.33 k | 18,634 |
28 May 24 | Solomon Moshkevich | Common Stock | Sell | Dispose S | No | Yes | 109.9595 | 1,647 | 181.10 k | 114,186 |
28 May 24 | John Fesko | Common Stock | Sell | Dispose S | No | Yes | 109.9595 | 1,438 | 158.12 k | 109,940 |
28 May 24 | Chapman Rowan E | Common Stock | Sell | Dispose S | No | No | 109.0874 | 4,856 | 529.73 k | 5,005 |
23 May 24 | Sheena Jonathan | Common Stock | Sell | Dispose S | Yes | Yes | 108.9144 | 236 | 25.70 k | 68,582 |
23 May 24 | Sheena Jonathan | Common Stock | Sell | Dispose S | Yes | Yes | 107.765 | 264 | 28.45 k | 68,818 |
23 May 24 | Sheena Jonathan | Common Stock | Sell | Dispose S | Yes | Yes | 109.1586 | 156 | 17.03 k | 68,582 |
23 May 24 | Sheena Jonathan | Common Stock | Sell | Dispose S | Yes | Yes | 107.9015 | 344 | 37.12 k | 68,738 |
News
Breaking Down Natera: 10 Analysts Share Their Views
3 Jun 24
Jefferies Initiates Coverage On Natera with Buy Rating, Announces Price Target of $142
3 Jun 24
(NTRA) - Analyzing Natera's Short Interest
31 May 24
Cathie Wood-Led Ark Invest Sells Nearly $28M Worth Of Robinhood Shares Amid Crypto API Launch And Lackluster Bitcoin Price Action
30 May 24
CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New AlloSure Process That It Believes Does Not Infringe On The '544 Patent.
29 May 24
Press releases
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
3 Jun 24
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
23 May 24
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
23 May 24
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
14 May 24
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
3 May 24